About
Rhinomed
Rhinomed is an airway technology company that seeks to radically improve the way you breathe, sleep, maintain your health and take medication.
Rhinomed’s patented nasal technology leverages the physiology of the nose to optimise our breathing which is essential to restful sleep and to maintaining good health.
Rhinomed’s vision for the future is to enable medications to be administered through the nose with the aim of improving the efficiency and effectiveness of the therapies, while seeking a reduction in side effects for patients.
Rhinomed continues to invest in furthering our knowledge of the role the nose, the upper airways and the olfactory system plays in maintaining health and wellness.
Rhinomed’s technology platform is protected by a family of over 60 patents globally. Rhinomed is headquartered in Melbourne, Australia.
Technology platform
Rhinomed’s nasal technology platform seeks to optimise the role the nose plays in your body’s physiology and the maintenance of good health. The technology platform aims to address significant unmet needs across four key areas of opportunity.
The Rhinomed platform is protected by a family of over 60 patents. These are granted and pending across the global market. Rhinomed continues to invest in furthering our knowledge of the role the nose, the upper airway and the olfactory system plays in maintaining health and wellness.
Rhinomed is actively seeking to partner with companies, research institutions and organisation whose interest coincide. Please reach out to us.
Board & Management
Rhinomed is led by a globally experienced team.
Michael Johnson
Managing Director & CEO
Michael is an experienced leader and innovator with a focus on the successful commercialisation of emerging technologies. Since joining Rhinomed in 2013 he has been responsible for the development of Rhinomed’s nasal technology platform and steering Rhinomed to being one of the world’s leading developers of wearable nasal medical technology. The company has now brought four products to market in the global sleep and snoring, respiratory and nasal congestion markets and is developing applications in the diagnostic and drug delivery markets. Over the course of his career he worked for a wide spectrum of companies from large multinationals through to start-up companies in Life Sciences, Cleantech, Financial Services and the Media and Communication industries. Michael received a Master’s in Entrepreneurship and Innovation (MEI) from Swinburne University and a Bachelor’s degree in Business from Monash University. Michael is a non-executive director of the US based Foundation for Airway Health.
RON DEWHURST
Chairman
Ron Dewhurst has spent 40 years spread across the Investment Banking and Asset Management Industries. He has worked internationally, including Hong Kong, the United Kingdom, and the United States of America, along with Australia. Ron has held leadership roles as CEO of ANZ McCaughan Ltd, Managing Director of IOOF Holdings Ltd, Head of Americas for J P Morgan Asset Management, and Executive Vice President and Head of Global Investment Managers for Legg Mason Inc.
Ron currently spends his time investing in and developing strategies in early stage companies. Ron has a long history of philanthropic pursuits. Ron is a strong advocate for diversity both broadly in the community, and more specifically in the business environment.
Ron is currently the Chairman of Sprott Inc. (TSX:SII), Executive Chairman and CEO of Cooper Investors Pty Ltd, and an Independent Director of LGIA Super Trustee.